Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor loading doses in STEMI
NCT01898442Phase 2
Key facts
- Status
- Completed
- Start
- Sep 2013
- Primary completion
- Jun 2014
- Countries
- 1
- Sponsor
- University of Florida
- Modality
- Small Molecules
- Drugs
- ticagrelor
- Conditions
- coronary artery disease (CAD)
01
Overview
Phase 2, randomised, open-label trial of ticagrelor in coronary artery disease (CAD) (3 arms), sponsored by University of Florida. Primary endpoint: Platelet Reactivity by VerifyNow P2Y12 at 1 hour. Started Sep 2013; status: completed.
02
Design
3 arms- Study design
- RandomizedOpen-label
Ticagrelor 180
Standard 180mg loading dose
Ticagrelor 270mg
High 270mg loading dose
Ticagrelor 360mg
High 360mg loading dose
03
Who it enrols
Patients with STEMI undergoing primary PCI, aged 18-80, with no prior P2Y12 use or high bleeding risk.
04
Endpoints
Primary
Platelet Reactivity by VerifyNow P2Y12
Secondary
Platelet Reactivity by VerifyNow P2Y12 at Other Time Points
Platelet Reactivity by Vasodilator-stimulated Phosphoprotein
Pharmacokinetic Profiles of Ticagrelor (Tmax)
Pharmacokinetic Profiles of Ticagrelor (Cmax)
Pharmacokinetic Profiles of Ticagrelor (AUC0-t)
Beyond the preview
Go deeper on NCT01898442.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01898442.